HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

TAS6417

pan-mutation-selective EGFR tyrosine kinase inhibitor

Also Known As:

CLN-081

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indolizines: 3
      - TAS6417: 2

Experts

1.	Abe, Naomi: 1 article (11/2019)
2.	Costa, Daniel B: 1 article (11/2019)
3.	Fujioka, Rumi: 1 article (11/2019)
4.	Fujita, Ryoto: 1 article (11/2019)
5.	Funabashi, Kaoru: 1 article (11/2019)
6.	Goto, Koichi: 1 article (11/2019)
7.	Hakozaki, Yumi: 1 article (11/2019)
8.	Haruma, Tomonori: 1 article (11/2019)
9.	Hasako, Shinichi: 1 article (11/2019)
10.	Hashimoto, Akihiro: 1 article (11/2019)

Related Diseases

1.

Lung Neoplasms (Lung Cancer)

11/01/2019 - "IMPLICATIONS: TAS6417/CLN-081 is a potent EGFR TKI with a wide therapeutic window and may be effective in lung cancer patients with clinically relevant EGFR mutations."
03/01/2023 - "Our preclinical data suggest a potential small molecule to overcome CLN-081 resistance, which may benefit patients with lung cancer with EGFR exon 20 insertions."
11/01/2019 - "Lung cancer and genetically engineered cell lines, as well as murine xenograft models were used to evaluate the efficacy of TAS6417 and other approved/in-development EGFR TKIs (erlotinib, afatinib, osimertinib, and poziotinib). "

Related Drugs and Biologics

1.	Afatinib
2.	Erlotinib Hydrochloride (CP 358,774)
3.	HM781-36B
4.	osimertinib